2 results
Approved WMORecruiting
- To evaluate the treatment efficiency by time to progression according to RECIST 1.1
Approved WMORecruiting
The primary objective of the trial is to evaluate whether nintedanib given as second-line therapy for advanced, inoperable and/or metastatic STSprolongs progression-free survival when compared with ifosfamide.Secondary objectives are to evaluate the…